PE20010302A1 - COMBINACION DE INHIBIDORES DE MTP E INHIBIDORES DE HMG-CoA REDUCTASA - Google Patents

COMBINACION DE INHIBIDORES DE MTP E INHIBIDORES DE HMG-CoA REDUCTASA

Info

Publication number: PE20010302A1
Authority: PE; Peru
Prior art keywords: alkyl; inhibitors; combination; phenyl; cycloalkyl
Prior art date: 1999-06-25

Application number

PE2000000625A

Other languages

English (en)

Spanish (es)

Inventor

Hilmar Bischoff

Ulrich Muller

Rudi Grutzmann

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-25

Filing date

2000-06-23

Publication date

2001-04-12

2000-06-23 Application filed by Bayer Ag filed Critical Bayer Ag

2001-04-12 Publication of PE20010302A1 publication Critical patent/PE20010302A1/es

Links

239000003112 inhibitor Substances 0.000 title abstract 3
229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
150000002367 halogens Chemical class 0.000 abstract 2
FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 abstract 1
SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical group [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical group F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
229960005370 atorvastatin Drugs 0.000 abstract 1
230000002425 cardiocirculatory effect Effects 0.000 abstract 1
229960005110 cerivastatin Drugs 0.000 abstract 1
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 abstract 1
208000029078 coronary artery disease Diseases 0.000 abstract 1
150000001925 cycloalkenes Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229960003765 fluvastatin Drugs 0.000 abstract 1
ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical class O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
229960004844 lovastatin Drugs 0.000 abstract 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
229960002797 pitavastatin Drugs 0.000 abstract 1
VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 abstract 1
229960002965 pravastatin Drugs 0.000 abstract 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
229960002855 simvastatin Drugs 0.000 abstract 1
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PE2000000625A 1999-06-25 2000-06-23 COMBINACION DE INHIBIDORES DE MTP E INHIBIDORES DE HMG-CoA REDUCTASA PE20010302A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19929065A DE19929065A1 (de)	1999-06-25	1999-06-25	Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln

Publications (1)

Publication Number	Publication Date
PE20010302A1 true PE20010302A1 (es)	2001-04-12

Family

ID=7912459

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2000000625A PE20010302A1 (es)	1999-06-25	2000-06-23	COMBINACION DE INHIBIDORES DE MTP E INHIBIDORES DE HMG-CoA REDUCTASA

Country Status (12)

Country	Link
EP (1)	EP1196194A2 (de)
JP (1)	JP2003503342A (de)
AR (1)	AR028996A1 (de)
AU (1)	AU5680900A (de)
CA (1)	CA2376881A1 (de)
DE (1)	DE19929065A1 (de)
DO (1)	DOP2000000022A (de)
GT (1)	GT200000099A (de)
PE (1)	PE20010302A1 (de)
SV (1)	SV2004000109A (de)
UY (1)	UY26218A1 (de)
WO (1)	WO2001000183A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10030375A1 (de) *	2000-06-21	2002-01-03	Bayer Ag	Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
BR0306292A (pt) *	2002-02-28	2004-08-24	Japan Tobacco Inc	Composto de éster e uso medicinal do mesmo
JP4832897B2 (ja) *	2003-08-29	2011-12-07	日本たばこ産業株式会社	エステル誘導体及びその医薬用途
US8101774B2 (en)	2004-10-18	2012-01-24	Japan Tobacco Inc.	Ester derivatives and medicinal use thereof
FR2884831B1 (fr) *	2005-04-22	2007-08-10	Merck Sante Soc Par Actions Si	Methode de criblage de composes inhibiteurs de la mtp
DE102011007272A1 (de)	2011-04-13	2012-10-18	Bayer Pharma Aktiengesellschaft	Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
US10905667B2 (en)	2018-07-24	2021-02-02	Bayer Pharma Aktiengesellschaft	Orally administrable modified-release pharmaceutical dosage form
CN109053927A (zh) *	2018-08-08	2018-12-21	中山大学	一种含维生素b12基团的两亲性海藻酸钠衍生物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4435477A1 (de) *	1994-10-04	1996-04-11	Bayer Ag	Cycloalkano-indol- und -azaindol-derivate
DE19546919A1 (de) *	1995-12-15	1997-06-19	Bayer Ag	N-Heterocyclisch substituierte Phenylessigsäure-Derivate
DE19546918A1 (de) *	1995-12-15	1997-06-19	Bayer Ag	Bicyclische Heterocyclen
DE19615265A1 (de) *	1996-04-18	1997-12-04	Bayer Ag	Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole
NZ335162A (en) *	1996-11-27	2000-01-28	Pfizer	Apo b-secretion/mtp inhibitory amides
AU748608B2 (en) *	1997-05-01	2002-06-06	Bristol-Myers Squibb Company	MTP inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

1999
- 1999-06-25 DE DE19929065A patent/DE19929065A1/de not_active Withdrawn
2000
- 2000-06-13 CA CA002376881A patent/CA2376881A1/en not_active Abandoned
- 2000-06-13 WO PCT/EP2000/005410 patent/WO2001000183A2/de not_active Ceased
- 2000-06-13 AU AU56809/00A patent/AU5680900A/en not_active Abandoned
- 2000-06-13 JP JP2001505893A patent/JP2003503342A/ja active Pending
- 2000-06-13 EP EP00942056A patent/EP1196194A2/de not_active Withdrawn
- 2000-06-21 GT GT200000099A patent/GT200000099A/es unknown
- 2000-06-22 AR ARP000103129A patent/AR028996A1/es unknown
- 2000-06-23 PE PE2000000625A patent/PE20010302A1/es not_active Application Discontinuation
- 2000-06-23 UY UY26218A patent/UY26218A1/es not_active Application Discontinuation
- 2000-06-23 SV SV2000000109A patent/SV2004000109A/es unknown
2008
- 2008-04-11 DO DO2000000022A patent/DOP2000000022A/es unknown

Also Published As

Publication number	Publication date
JP2003503342A (ja)	2003-01-28
EP1196194A2 (de)	2002-04-17
GT200000099A (es)	2001-12-13
DOP2000000022A (es)	2008-08-15
AR028996A1 (es)	2003-06-04
UY26218A1 (es)	2001-01-31
CA2376881A1 (en)	2001-01-04
DE19929065A1 (de)	2000-12-28
WO2001000183A3 (de)	2001-05-10
SV2004000109A (es)	2004-05-07
WO2001000183A2 (de)	2001-01-04
AU5680900A (en)	2001-01-31

Legal Events

Date	Code	Title	Description
2004-05-31	FG	Grant, registration
2009-01-27	FD	Application declared void or lapsed

Publication	Publication Date	Title
PE20011294A1 (es)	2001-12-21	Composiciones farmaceuticas de agonistas/antagonistas de estrogeno y estatinas para tratar la osteoporosis y reducir el colesterol
PE20020254A1 (es)	2002-04-03	Derivados de piridina
PE20001054A1 (es)	2000-10-14	1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-amino sustituidas
PE20030497A1 (es)	2003-07-04	Combinaciones de un inhibidor de pde 5 y otros agentes activos
ATE444065T1 (de)	2009-10-15	4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-deriva e als pde-4-hemmer zur behandlung von neurologischen syndromen
TR199900400T2 (xx)	1999-05-21	Heterosiklik metaloproteaz inhibit�rleri.
PE20060777A1 (es)	2006-10-06	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
UY27992A1 (es)	2004-04-30	Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht
AR016314A1 (es)	2001-07-04	Derivados de piridina, su uso como medicamentos y composiciones farmaceuticas que los contienen
PE20010302A1 (es)	2001-04-12	COMBINACION DE INHIBIDORES DE MTP E INHIBIDORES DE HMG-CoA REDUCTASA
CO5550436A2 (es)	2005-08-31	Derivados de benzamida
DE60131160D1 (de)	2007-12-13	Caspase-inhibitoren und ihre verwendungen
ECSP045368A (es)	2005-01-03	"antagonistas de los receptores de trombina"
PA8444301A1 (es)	2000-05-24	Compuestos de quinolina y de quinazolina utiles en terapia
ATE328879T1 (de)	2006-06-15	Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv
AR049696A1 (es)	2006-08-30	Derivados de indol
CO5611143A2 (es)	2006-02-28	Profarmacos de fosfatos de fluorooxindoles
TR199900429T2 (xx)	1999-05-21	Spirosiklik metaloproteaz inhibit�rleri.
DE60027700D1 (de)	2006-06-08	Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden
PE20020253A1 (es)	2002-04-08	Derivados de 3-azabiciclo[3.1.0]hexano como ligandos de receptores opiaceos
ATE444299T1 (de)	2009-10-15	Neue boronatester
ATE342261T1 (de)	2006-11-15	Pyranderivate als inhibitoren von ace und nep
PE20000017A1 (es)	2000-01-20	Combinaciones de estatina-eter carboxialquilico
ATE277893T1 (de)	2004-10-15	N-(2-phenyl-4-amino-butyl)-1-naphthamide als neurokinin-1 rezeptorantagonisten
BRPI0417138A (pt)	2007-02-21	n-alquil-pirroles como inibidores de hmg-coa-redutase